Prosecution Insights
Last updated: October 02, 2026

Food And Drug Administration

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Food And Drug Administration maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently features 1 pending office action. This single action is assigned to 1 distinct examiner, which represents the current point of interaction with the USPTO.

The work is conducted within 1 distinct art unit, aligning with the requirements of the Biotechnology & Pharmaceuticals field. Jianfeng Song is the busiest examiner for this portfolio and is currently responsible for the 1 pending office action. As there is 1 pending action, this examiner handles the current active correspondence for the company.

Practitioners should note that the outcome of this 1 pending office action is the current focus for the development of the portfolio. The involvement of 1 distinct examiner and 1 distinct art unit means that the prosecution strategy is directed toward a single individual and unit. Success in this 1 pending office action will depend on addressing the specific concerns of Jianfeng Song within the context of the 1 distinct art unit.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
0
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
0
Due this month
1
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Double-patenting + other1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SONG, JIANFENG 1 56.3% +33.2%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18354345 COMPOSITIONS AND METHODS FOR FILTERING MICROORGANISMS FROM A FLUID SONG, JIANFENG 39d

Top Art Units

Art UnitApps
1613 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18354345 COMPOSITIONS AND METHODS FOR FILTERING MICROORGANISMS FROM A FLUID SONG, JIANFENG 1613 §103DP Final Rejection 39d Pending Jul 18, 2023

Managing Food And Drug Administration's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month